Following expert discussions, clinical application for each type of cell (clinical studies or trials) are now scheduled as follows (in parentheses the schedules announced in February 2013).
2016 or 2017: dopamine-producing nerve cells (2016-2018)
2018: neural stem cells guideline (within 2018)
2016-2017: cornea (within 2017)
2014: retinal pigment epithelium (2014-2015)
2018-2019: visual cells (2016-2017)
2017: myocardium guideline (2016-2018)
2016 platelet guideline (2016-2017)
2017 – 2018: NKT cells (new)
2022 or later: red blood cells (from 2018)
2025 or later: hematopoietic stem cells (2020-2023)
2019: liver guideline (2018)
2019: pancreatic β cells guideline (from 2018)
2023: pituitary guideline (new)
2025 or later: kidney (from 2023)
2017-2018: cartilage (from 2020)
2020-2021: skeletal muscle (from 2020)
2019-2020: hair follicle (new)
2020-2021 glands (new)
2022 or later: teeth (new)

Nikkei Biotech, December 8, 2015